Granite Point Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Granite Point Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-140,000	Closed	-$2.74M	–	89
2022 Q4	$2.74M	Buy	140,000 +20,000	+17%	+$368K	1.75%	15
2022 Q3	$1.92M	Buy	120,000 +40,000	+50%	+$624K	0.78%	23
2022 Q2	$1.1M	Buy	+80,000	New	+$954K	0.28%	40

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Granite Point Capital Management's RCKT Position: Q1 2023 in Review

Granite Point Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 140,000 shares — an estimated $2.74M sold.

Granite Point Capital Management first reported a position in RCKT in Q2 2022 and held it in 3 quarters. The position peaked at $2.74M in Q4 2022. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

Granite Point Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Granite Point Capital Management sold 140,000 Rocket Pharmaceuticals shares in Q1 2023, an estimated $2.74M.
Granite Point Capital Management first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 3 quarters.
Granite Point Capital Management's Rocket Pharmaceuticals position peaked at $2.74M in Q4 2022.
163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on Granite Point Capital Management's 13F filing for Q1 2023, filed 11 May 2023.